M. Monreal

Publications585
h-index63
Citations16,237
Highly Influential Citations462
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • S. Goldhaber
  • 819 Publications • 58,917 Citations
  • P. Prandoni
  • 608 Publications • 36,454 Citations
  • G. Agnelli
  • 630 Publications • 36,189 Citations
  • P. Wells
  • 347 Publications • 25,132 Citations
  • Publications
  • Influence
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
Abstract Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), may predispose patients to thrombotic… Expand
  • 910
  • 42
Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism.
BACKGROUND The Pulmonary Embolism Severity Index (PESI) estimates the risk of 30-day mortality in patients with acute pulmonary embolism (PE). We constructed a simplified version of the PESI. … Expand
  • 751
  • 28
  • PDF
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
Summary.  Background: Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been suboptimal worldwide. Objectives: To… Expand
  • 493
  • 16
  • PDF
Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry.
BACKGROUND There is little information on the clinical outcome of patients with upper-extremity deep vein thrombosis (DVT). METHODS RIETE is an ongoing registry of consecutive patients with… Expand
  • 234
  • 15
  • PDF
Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism.
BACKGROUND Evidence-based guidelines recommend that acutely ill hospitalized medical patients who are at risk of venous thromboembolism (VTE) should receive prophylaxis. Our aim was to characterize… Expand
  • 480
  • 14
Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry.
A score that can accurately determine the risk of major bleeding during anticoagulant therapy may help to make decisions on anticoagulant use. RIETE is an ongoing registry of consecutive patients… Expand
  • 359
  • 13
  • PDF
Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial
Summary.  Patients with symptomatic idiopathic venous thromboembolism and apparently cancer‐free have an approximate 10% incidence of subsequent cancer. Apparently cancer‐free patients with acute… Expand
  • 284
  • 12
Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility
BACKGROUND Extended-duration low-molecular-weight heparin has been shown to prevent venous thromboembolism (VTE) in high-risk surgical patients. OBJECTIVE To evaluate the efficacy and safety of… Expand
  • 301
  • 11
  • PDF
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.
Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer. These patients are at a high risk of VTE recurrence and bleeding during anticoagulant therapy. The… Expand
  • 110
  • 10
Upper extremity deep venous thrombosis in cancer patients with venous access devices--prophylaxis with a low molecular weight heparin (Fragmin).
Central venous access devices are often essential for the administration of chemotherapy to patients with malignancy, but its use has been associated with a number of complications, mainly… Expand
  • 374
  • 9
...
1
2
3
4
5
...